Platform Technology Partners Gamida Cell Ltd. Transaction History

Platform Technology Partners

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	BUY	$0.25 - $1.02 $2,000 - $8,160	8,000 Added 10.08%	87,353 $35,000
Q2 2023 Jul 12, 2023	BUY	$0.73 - $2.37 $4,947 - $16,063	6,778 Added 9.34%	79,353 $153,000
Q1 2023 Apr 04, 2023	BUY	$0.68 - $1.71 $3,740 - $9,405	5,500 Added 8.2%	72,575 $58,000
Q4 2022 Jan 11, 2023	BUY	$1.15 - $2.1 $7,474 - $13,650	6,500 Added 10.73%	67,075 $0
Q3 2022 Oct 24, 2022	BUY	$1.53 - $3.39 $4,513 - $10,000	2,950 Added 5.12%	60,575 $96,000
Q2 2022 Aug 04, 2022	BUY	$1.73 - $4.29 $3,460 - $8,580	2,000 Added 3.6%	57,625 $102,000
Q1 2022 May 03, 2022	BUY	$2.22 - $4.47 $1,110 - $2,235	500 Added 0.91%	55,625 $231,000
Q4 2021 Feb 01, 2022	SELL	$2.2 - $4.46 $1,650 - $3,345	-750 Reduced 1.34%	55,125 $140,000
Q3 2021 Nov 04, 2021	BUY	$3.85 - $6.44 $40,425 - $67,620	10,500 Added 23.14%	55,875 $219,000
Q2 2021 Aug 05, 2021	BUY	$5.85 - $8.33 $265,443 - $377,973	45,375 New	45,375 $291,000

2.2K

Ticker GMDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,319,600
Market Cap $2.29M
Description
Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials ...

Get notified when there are updates to the investment portfolio of Platform Technology Partners, based on Form 13F filings with the SEC.

Stay updated on Platform Technology Partners with notifications on news.